Nucor earnings beat by $0.08, revenue fell short of estimates
WILMINGTON, MA—Top executives at Charles River Laboratories International, Inc. have recently made significant purchases of the company’s stock, according to a new filing with the Securities and Exchange Commission. On February 20, 2025, James C. Foster, Chairman, President, and CEO, acquired 6,075 shares at an average price of $165.01, totaling approximately $1 million. Additionally, Birgit Girshick, Corporate Executive Vice President and COO, purchased 1,514 shares at an average price of $164.63, amounting to roughly $250,000.
These transactions come in the wake of both executives terminating their respective Rule 10b5-1 Trading Plans, which were designed to allow for the sale of company stock at predetermined times and prices. Foster’s plan, set on February 26, 2024, initially permitted the sale of up to 129,721 shares. He terminated the plan to facilitate his recent stock purchase and to avoid potential violations of short swing profit rules. Prior to termination, Foster sold 25,000 shares under this plan on August 1, 2024. Similarly, Girshick ended her plan, created on November 22, 2023, which allowed for the sale of up to 22,362 shares. She made no sales before the termination.
The executives’ stock purchases are reported as expressions of their confidence in Charles River Laboratories’ strategic direction and long-term growth prospects. These transactions will be separately disclosed on Forms 4 filed with the SEC.
Charles River Laboratories, headquartered in Wilmington, Massachusetts, is known for its commercial physical and biological research services. The company has been a key player in the industry, with a history of providing a variety of services in the field of preclinical and clinical laboratory services. With a market capitalization of $8.3 billion and annual revenue of $4.05 billion, the company maintains a solid financial position with a FAIR overall health score according to InvestingPro’s comprehensive analysis.
The information disclosed in this article is based on the company’s recent SEC filing and includes forward-looking statements regarding the company’s strategic direction and growth prospects. These statements are subject to risks and uncertainties that could cause actual results to differ materially.
Investors and the market will be watching closely to see how these purchases by company insiders reflect on the company’s performance and investor confidence moving forward. Analyst sentiment remains mixed, with price targets ranging from $130 to $260 per share, though net income is expected to grow this year. For deeper insights into Charles River Laboratories’ financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Charles River Laboratories reported its fourth-quarter 2024 earnings, surpassing analyst expectations with earnings per share (EPS) of $2.66 compared to the forecasted $2.54. Revenue also exceeded projections, reaching $1 billion against the anticipated $985.18 million. Despite these positive results, Evercore ISI revised its price target for Charles River Labs (NYSE:CRL) to $175 from $195, maintaining an "In Line" rating. The firm acknowledged the company’s realistic outlook for 2025, aligning with current demand conditions. Charles River Labs anticipates a 3.5% to 5.5% organic revenue decline in 2025, with non-GAAP EPS projected between $9.10 and $9.60. The company plans to repurchase approximately $350 million in stock to enhance shareholder value. Despite ongoing demand constraints, Charles River Labs continues to implement cost-cutting initiatives and strategic restructuring to navigate the challenging biopharmaceutical environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.